Fireman B.V. or InflaRx
http://www.inflarx.com/Overview
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 12
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 9, 2021 | InflaRx N : 09-2021-InflaRx to Present at the H.C. Wainwright 23rd Annual Global Investment Conference | Jena, Germany, September 9, 2021 - InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announces that Prof. Niels C. Riedemann, Chief Executive Off... |
| May 12, 2021 | INFLARX N.V. InflaRx N : 05-2021-InflaRx Reports First Quarter 2021 Financial & Operating Results | Jena, Germany, May 12, 2021 - InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today financial results for the three months ended Marc... |
| May 11, 2021 | INFLARX N.V. InflaRx N : 05-2021-InflaRx Announces Positive Topline Results for Vilobelimab from the U.S. Phase II ANCA-Associated Vasculitis IXPLORE Study | U.S. IXPLORE Phase II trial achieved its objective; vilobelimab was shown to be safe and well tolerated in patients with ANCA-associated vasculitis when added to current standard of care EU IXCHANGE Phase II trial is fully enrolled with res... |
| Nov 8, 2017 | Term Sheet — Wednesday, November 8 | 5 Qs WITH A DEALMAKER Snap revealed some worse-than-expected earnings in the third quarter and a $40 million Spectacles flop during its earnings call on Tuesday. CEO Evan Spiegel noted that the company will redesign the app “to make it easi... |
| Oct 16, 2017 | Term Sheet — Monday, October 16 | MONDAY KICKOFF Good morning, Term Sheet readers. Paid Content You can't secure what you can't see From ExtraHop AMERICA’S MOST ACTIVE: Here’s an interesting tidbit to start off your week — Boston takes the title for most active bu... |
| Oct 13, 2017 | InflaRx Raises $55M in Series D Funding | InflaRx, a Jena and Munich, Germany-based biopharmaceutical company developing new therapeutics in the terminal complement space, raised $55M in Series D funding. The round, comprised of a $30M capital increase and a $ 25M secondary share p... |
| Jul 17, 2014 | InflaRx Closes Series B Financing | InflaRx, a Jena, Germany-based developer of new therapeutics in the field of acute and chronic inflammation, closed its double digit million Euro round B financing by completing the second of two tranches within this round. Lead investor wa... |
| InflaRx Announces Decision to Enter Phase III Development of IFX‑1 in Severe COVID-19 Induced Pneumonia | 50% lower all-cause mortality rate and other efficacy trends were shown with IFX‑1 in initial data from the randomized exploratory Phase II part of the Phase II/III trial Subject to regulatory approval, a randomized, double-bli... | |
| bm|t Investee Partner InflaRx selected for COVID-19 Therapy Offensive of the German Federal Ministry of Education and Research | The German Federal Ministry of Education and Research has announced the first six funded biotech companies in its COVID-19 therapy initiative, which is being funded with up to €300 million. The funding is intended to financiall... |
Reviews 0
FAQ about Fireman B.V. or InflaRx
How much funding has Fireman B.V. or InflaRx raised?
Fireman B.V. or InflaRx has raised $55M in total across 1 funding round.
What has the press written about Fireman B.V. or InflaRx?
Parsers VC has collected 12 articles mentioning Fireman B.V. or InflaRx, among them “InflaRx N : 09-2021-InflaRx to Present at the H.C. Wainwright 23rd Annual Global Investment Conference” (Sep 9, 2021) and “INFLARX N.V. InflaRx N : 05-2021-InflaRx Reports First Quarter 2021 Financial & Operating Results” (May 12, 2021).
Is Fireman B.V. or InflaRx still active?
Yes, Fireman B.V. or InflaRx is active; its latest activity on Parsers VC dates from Jan 5, 2022.